Dr. Min Fang 方敏
Chief Physician
Department of Thoracic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Heavy ion radiotherapy, chemotherapy, immunotherapy, and targeted therapy for lung cancer, esophageal cancer, breast cancer, and mediastinal tumors.
Dr. Fang is Chief Physician, Assistant Department Director, and Secretary of the Heavy Ion Medical Center at Zhejiang Cancer Hospital. Holding a medical doctorate and postdoctoral fellowship from Zhejiang University, Dr. Fang treats thoracic tumors using heavy ion radiotherapy and comprehensive care. Research focuses on immunotherapy for lung and esophageal cancers, and prevention of radiation pneumonitis and pulmonary fibrosis. Dr. Fang has led multiple national and provincial grants and published nearly 20 academic papers.
Professional roles
- Member of the First Youth Committee, Precision Oncology Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Fang Min). Papers usually list the name as Min Fang or Fang M.
Selected publications
25 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Curr Probl Cancer, 2024 (senior author): A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy. PubMed 38704949
- Curr Mol Med, 2024 (senior author): The Preventive Effect of Endostar on Radiation-induced Pulmonary Fibrosis. PubMed 37038709
- Clin Exp Metastasis, 2023 (first author): Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world. PubMed 37584783
- Oncol Lett, 2023 (senior author): Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC. PubMed 36844625
- Front Oncol, 2022 (first author): Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer in real world. PubMed 36713546
- Oncol Lett, 2018 (first author): The heterogenic tumor microenvironment of hepatocellular carcinoma and prognostic analysis based on tumor neo-vessels, macrophages and α-SMA. PubMed 29552120
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion